Symbols / LTRN Stock $3.14 +0.32% Lantern Pharma Inc.

Healthcare • Biotechnology • United States • NCM
LTRN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Panna Sharma
Exch · Country NCM · United States
Market Cap 40.06M
Enterprise Value 25.30M
Income -17.12M
Sales —
FCF (ttm) -9.18M
Book/sh 0.58
Cash/sh 0.90
Employees 16
Insider 10d —
IPO Jun 11, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.55
PEG —
P/S —
P/B 5.40
P/C —
EV/EBITDA -1.41
EV/Sales —
Quick Ratio 2.25
Current Ratio 2.40
Debt/Eq 1.20
LT Debt/Eq —
EPS (ttm) -1.57
EPS next Y -2.02
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-12
Earnings (prior) 2026-05-15
ROA -61.39%
ROE -123.51%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 12.76M
Shs Float 8.57M
Insider Own 17.15%
Instit Own 16.30%
Short Float 17.90%
Short Ratio 1.73
Short Interest 2.02M
52W High 5.74
vs 52W High -45.33%
52W Low 1.11
vs 52W Low 182.88%
Beta 2.10
Impl. Vol. 2.15%
Rel Volume 0.86
Avg Volume 627.55K
Volume 541.97K
Target (mean) $20.00
Tgt Median $20.00
Tgt Low $15.00
Tgt High $25.00
# Analysts 2
Recom None
Prev Close $3.13
Price $3.14
Change 0.32%
About

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$20.00
Mean price target
2. Current target
$3.14
Latest analyst target
3. DCF / Fair value
$-12.95
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.14
Low
$15.00
High
$25.00
Mean
$20.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-04-02 init Lake Street — → Buy $25
2024-04-25 reit HC Wainwright & Co. — → Neutral —
2023-08-10 reit EF Hutton Buy → Buy $11
2023-06-26 main EF Hutton Buy → Buy $11
2023-05-18 init HC Wainwright & Co. — → Neutral —
2023-03-21 reit EF Hutton — → Buy $11
2023-02-15 main EF Hutton — → Buy $11
2022-11-01 init EF Hutton — → Buy $11
2022-03-11 main HC Wainwright & Co. — → Buy $36
2021-11-02 main HC Wainwright & Co. — → Buy $34
2021-10-07 init HC Wainwright & Co. — → Buy $32
2020-07-28 init Colliers Securities — → Buy $24
News
RSS: Latest LTRN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-12 KEYSER DONALD JEFFREY PH.D Director — 48,544 $2.06 $100,001
2025-06-13 KREIS LESLIE W JR Beneficial Owner of more than 10% of a Class of Security — 40,000 $3.09 $123,600
2025-06-12 KREIS LESLIE W JR Beneficial Owner of more than 10% of a Class of Security — 61,613 $3.38 $208,271
2025-05-29 KREIS LESLIE W JR Beneficial Owner of more than 10% of a Class of Security — 56,237 $2.87 $168,419
2024-07-24 KEYSER DONALD JEFFREY PH.D Director — 3,832 $4.42 $16,937
2024-05-24 KREIS LESLIE W JR Beneficial Owner of more than 10% of a Class of Security — 30,000 $6.25 $189,100
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
17.98
-19.08%
22.22
+24.27%
17.88
+23.87%
14.43
Research And Development
11.51
-28.60%
16.13
+35.57%
11.89
+38.26%
8.60
Selling General And Administration
6.46
+6.13%
6.09
+1.80%
5.98
+2.63%
5.83
General And Administrative Expense
6.46
+6.13%
6.09
+1.80%
5.98
+2.63%
5.83
Other Gand A
6.46
+6.13%
6.09
+1.80%
5.98
+2.63%
5.83
Total Expenses
17.98
-19.08%
22.22
+24.27%
17.88
+23.87%
14.43
Operating Income
-17.98
+19.08%
-22.22
-24.27%
-17.88
-23.87%
-14.43
Total Operating Income As Reported
-17.98
+19.08%
-22.22
-24.27%
-17.88
-23.87%
-14.43
EBITDA
-17.96
+19.09%
-22.20
-24.27%
-17.86
-23.85%
-14.42
Normalized EBITDA
-17.96
+19.09%
-22.20
-24.27%
-17.86
-23.85%
-14.42
Reconciled Depreciation
0.02
-0.01%
0.02
+18.25%
0.01
+44.98%
0.01
EBIT
-17.98
+19.08%
-22.22
-24.27%
-17.88
-23.87%
-14.43
Net Income
-17.12
+17.62%
-20.78
-30.20%
-15.96
-11.93%
-14.26
Pretax Income
-17.12
+17.62%
-20.78
-30.20%
-15.96
-11.93%
-14.26
Net Non Operating Interest Income Expense
0.44
-41.01%
0.74
-3.01%
0.77
+274.54%
0.20
Net Interest Income
0.44
-41.01%
0.74
-3.01%
0.77
+274.54%
0.20
Interest Income Non Operating
0.44
-41.01%
0.74
-3.01%
0.77
+274.54%
0.20
Interest Income
0.44
-41.01%
0.74
-3.01%
0.77
+274.54%
0.20
Other Income Expense
0.42
-39.22%
0.69
-39.78%
1.15
+3747.29%
-0.03
Other Non Operating Income Expenses
0.42
-39.22%
0.69
-39.78%
1.15
+3747.29%
-0.03
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-17.12
+17.62%
-20.78
-30.20%
-15.96
-11.93%
-14.26
Net Income From Continuing Operation Net Minority Interest
-17.12
+17.62%
-20.78
-30.20%
-15.96
-11.93%
-14.26
Net Income From Continuing And Discontinued Operation
-17.12
+17.62%
-20.78
-30.20%
-15.96
-11.93%
-14.26
Net Income Continuous Operations
-17.12
+17.62%
-20.78
-30.20%
-15.96
-11.93%
-14.26
Normalized Income
-17.12
+17.62%
-20.78
-30.20%
-15.96
-11.93%
-14.26
Net Income Common Stockholders
-17.12
+17.62%
-20.78
-30.20%
-15.96
-11.93%
-14.26
Diluted EPS
—
-1.93
-31.29%
-1.47
-12.21%
-1.31
Basic EPS
—
-1.93
-31.29%
-1.47
-12.21%
-1.31
Basic Average Shares
—
10.76
-0.74%
10.84
-0.08%
10.85
Diluted Average Shares
—
10.76
-0.74%
10.84
-0.08%
10.85
Diluted NI Availto Com Stockholders
-17.12
+17.62%
-20.78
-30.20%
-15.96
-11.93%
-14.26
Line Item Trend 2023-12-31
Total Assets
43.65
Current Assets
43.34
Cash Cash Equivalents And Short Term Investments
41.30
Cash And Cash Equivalents
21.94
Cash Equivalents
20.88
Cash Financial
1.06
Other Short Term Investments
19.36
Prepaid Assets
—
Restricted Cash
0.00
Other Current Assets
2.04
Total Non Current Assets
0.31
Net PPE
0.28
Gross PPE
0.28
Other Properties
0.28
Non Current Deferred Assets
—
Other Non Current Assets
0.03
Total Liabilities Net Minority Interest
2.74
Current Liabilities
2.68
Payables And Accrued Expenses
2.51
Current Debt And Capital Lease Obligation
0.17
Current Capital Lease Obligation
0.17
Total Non Current Liabilities Net Minority Interest
0.06
Long Term Debt And Capital Lease Obligation
0.06
Long Term Capital Lease Obligation
0.06
Stockholders Equity
40.91
Common Stock Equity
40.91
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
10.72
Ordinary Shares Number
10.72
Treasury Shares Number
0.00
Additional Paid In Capital
96.26
Retained Earnings
-55.24
Gains Losses Not Affecting Retained Earnings
-0.11
Other Equity Adjustments
-0.11
Total Equity Gross Minority Interest
40.91
Total Capitalization
40.91
Working Capital
40.66
Invested Capital
40.91
Total Debt
0.23
Capital Lease Obligations
0.23
Net Tangible Assets
40.91
Tangible Book Value
40.91
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-15.68
+11.99%
-17.81
-24.16%
-14.35
-12.37%
-12.77
Cash Flow From Continuing Operating Activities
-15.68
+11.99%
-17.81
-24.16%
-14.35
-12.37%
-12.77
Net Income From Continuing Operations
-17.12
+17.62%
-20.78
-30.20%
-15.96
-11.93%
-14.26
Depreciation Amortization Depletion
0.02
-0.01%
0.02
+18.25%
0.01
+44.98%
0.01
Depreciation And Amortization
0.02
-0.01%
0.02
+18.25%
0.01
+44.98%
0.01
Other Non Cash Items
0.56
+221.46%
0.17
+8.10%
0.16
+10.81%
0.14
Stock Based Compensation
0.65
-11.19%
0.73
-31.35%
1.07
-10.12%
1.19
Operating Gains Losses
0.08
-59.87%
0.21
+65.43%
0.13
-32.09%
0.19
Gain Loss On Investment Securities
0.24
+2775.18%
-0.01
-107.83%
0.12
-10.15%
0.13
Unrealized Gain Loss On Investment Securities
-0.31
-96.56%
-0.16
-30.07%
-0.12
-124.29%
0.49
Net Foreign Currency Exchange Gain Loss
-0.16
-171.89%
0.22
+1810.69%
0.01
-80.37%
0.06
Change In Working Capital
0.64
-71.49%
2.23
+314.14%
0.54
+187.93%
-0.61
Change In Prepaid Assets
0.55
-28.81%
0.78
-17.33%
0.94
+191.06%
-1.03
Change In Payables And Accrued Expense
0.27
-83.39%
1.64
+792.88%
-0.24
-140.70%
0.58
Change In Other Current Assets
0.00
+100.00%
-0.01
-36.20%
-0.01
0.00
Change In Other Current Liabilities
-0.19
-8.49%
-0.18
-10.34%
-0.16
-0.54%
-0.16
Investing Cash Flow
11.06
+228.16%
3.37
+462.22%
-0.93
-618.89%
0.18
Cash Flow From Continuing Investing Activities
11.06
+228.16%
3.37
+462.22%
-0.93
-618.89%
0.18
Net PPE Purchase And Sale
-0.00
+86.38%
-0.01
+32.77%
-0.02
+32.72%
-0.03
Purchase Of PPE
-0.00
+86.38%
-0.01
+32.77%
-0.02
+32.72%
-0.03
Capital Expenditure
-0.00
+86.38%
-0.01
+32.77%
-0.02
+32.72%
-0.03
Net Investment Purchase And Sale
11.06
+226.99%
3.38
+471.04%
-0.91
-540.09%
0.21
Purchase Of Investment
-14.72
+14.78%
-17.28
-110.78%
-8.20
-109.48%
-3.91
Sale Of Investment
25.78
+24.80%
20.66
+183.58%
7.28
+76.83%
4.12
Financing Cash Flow
1.50
+2145.90%
0.07
+113.34%
-0.50
+77.09%
-2.18
Cash Flow From Continuing Financing Activities
1.50
+2145.90%
0.07
+113.34%
-0.50
+77.09%
-2.18
Net Issuance Payments Of Debt
—
—
—
—
Issuance Of Debt
—
—
—
—
Repayment Of Debt
—
—
—
—
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
1.62
0.00
+100.00%
-0.50
+79.86%
-2.48
Common Stock Payments
—
—
-0.50
+79.86%
-2.48
Repurchase Of Capital Stock
—
—
-0.50
+79.86%
-2.48
Proceeds From Stock Option Exercised
0.01
-79.85%
0.07
0.00
-100.00%
0.30
Net Other Financing Charges
-0.14
—
-0.50
—
Changes In Cash
-3.12
+78.29%
-14.38
+8.87%
-15.78
-6.81%
-14.77
Effect Of Exchange Rate Changes
0.03
+167.46%
-0.05
-74.08%
-0.03
-168.33%
-0.01
Beginning Cash Position
7.51
-65.76%
21.94
-41.88%
37.74
-28.14%
52.52
End Cash Position
4.42
-41.12%
7.51
-65.76%
21.94
-41.88%
37.74
Free Cash Flow
-15.68
+12.04%
-17.83
-24.09%
-14.37
-12.27%
-12.80
Amortization Of Securities
-0.20
+17.67%
-0.24
-37.84%
-0.17
-311.42%
0.08
Common Stock Issuance
1.62
0.00
—
0.00
Issuance Of Capital Stock
1.62
0.00
—
0.00
Net Preferred Stock Issuance
—
—
—
-2.48
Preferred Stock Payments
—
—
—
-2.48
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category